HA
RNAM

HHLR Advisors’s Avidity Biosciences RNAM Stock Holding History

HHLR Advisors’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-425,000
Closed -$10.5M – 104
2021
Q2 		$10.5M Hold
425,000
– – 0.11% 67
2021
Q1 		$9.27M Hold
425,000
– – 0.09% 66
2020
Q4 		$10.8M Hold
425,000
– – 0.09% 71
2020
Q3 		$12M Hold
425,000
– – 0.09% 60
2020
Q2 		$12M Buy
+425,000
New +$12.3M 0.11% 51

Other funds holding RNAM

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HHLR Advisors's RNAM Position: Q3 2021 in Review

HHLR Advisors sold out of Avidity Biosciences (RNAM) in Q3 2021, closing a stake of 425,000 shares — an estimated $10.5M sold.

HHLR Advisors first reported a position in RNAM in Q2 2020 and held it in 5 quarters. The position peaked at $12M in Q2 2020. 111 funds tracked by Wall St. Rank hold RNAM as of Q3 2021.

  • HHLR Advisors reported no remaining Avidity Biosciences position as of Q3 2021 after selling out during the quarter.
  • HHLR Advisors sold 425,000 Avidity Biosciences shares in Q3 2021, an estimated $10.5M.
  • HHLR Advisors first reported a position in Avidity Biosciences in Q2 2020 and held it in 5 quarters.
  • HHLR Advisors's Avidity Biosciences position peaked at $12M in Q2 2020.
  • 111 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2021.

Based on HHLR Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.